XML 37 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business (Details)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
$ / shares
May 31, 2016
item
Apr. 01, 2016
Corporate Information, Status of Operations and Management Plans        
Number of Fabry causing mutations included in the label approved by the CHMP | item     313  
Net product sales $ 4,169      
Common stock, par value (in dollars per share) | $ / shares $ 0.01 $ 0.01    
Accumulated deficit $ (834,600) $ (779,608)    
Maximum        
Corporate Information, Status of Operations and Management Plans        
Percentage of patients with Fabry disease caused by mutations included in the label approved by the CHMP       0.5
Galafold | EU        
Corporate Information, Status of Operations and Management Plans        
Net product sales $ 4,200